The potential impact of a probiotic: Akkermansia muciniphila in the regulation of blood pressure—the current facts and evidence

• Published in: Journal of translational medicine Vol. 20; no. 1; pp. 1 - 15
• Main Authors: Lakshmanan, Arun Prasath, Murugesan, Selvasankar, Al Khodor, Souhaila, Terranegra, Annalisa
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 24.09.2022; BioMed Central; BMC
• Subjects: Akkermansia muciniphila; Bacteria; Blood pressure; Carbohydrates; Cardiovascular diseases; Diabetes; Diet; Digestive system; Fatty acids; Gene expression; Glucose; Gut microbiome; Gut microbiota; Health aspects; Homeostasis; Hypertension; Intestinal microflora; Kidney diseases; Metagenomic; Microbiota; Microbiota (Symbiotic organisms); Nervous system; Pathophysiology; Peptides; Probiotics; Review; Risk factors; Testing; Therapeutic targets; Qatar
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-022-03631-0

Akkermansia muciniphila ( A. muciniphila ) is present in the human gut microbiota from infancy and gradually increases in adulthood. The potential impact of the abundance of A. muciniphila has been studied in major cardiovascular diseases including elevated blood pressure or hypertension (HTN). HTN is a major factor in premature death worldwide, and approximately 1.28 billion adults aged 30–79 years have hypertension. A. muciniphila is being considered a next-generation probiotic and though numerous studies had highlighted the positive role of A. muciniphila in lowering/controlling the HTN, however, few studies had highlighted the negative impact of increased abundance of A. muciniphila in the management of HTN. Thus, in the review, we aimed to discuss the current facts, evidence, and controversy about the role of A . muciniphila in the pathophysiology of HTN and its potential effect on HTN management/regulation, which could be beneficial in identifying the drug target for the management of HTN.